{"id":313306,"date":"2026-10-16T11:45:28","date_gmt":"2026-10-16T06:15:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=313306"},"modified":"2026-10-16T11:45:28","modified_gmt":"2026-10-16T06:15:28","slug":"venusrem-best-stock-in-its-sector","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/","title":{"rendered":"Is Venus Remedies the Best Stock in Its Sector? A Look at the Numbers"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Venus Remedies CMP Rs 1,572 (16 Oct 2026). Market cap Rs 2,091 Cr. ROE 15.49%. P\/E 18.00x versus Industry P\/E 36.42x.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Venus Remedies is one of the names investors compare when screening the Pharmaceuticals sector. Whether it is the best stock in its sector depends on whether an investor prioritises return ratios, valuation or balance sheet strength. This article sets it against two named peers and the sector benchmark so you can judge for yourself.<\/p>\n<\/p><\/div>\n<p>Is <a href=\"https:\/\/univest.in\/stocks\/venusrem\/venus-remedies-ltd-share-price-today\">Venus Remedies<\/a> the best stock in its sector? The stock trades on the NSE at Rs 1,572 as of 16 October 2026, within its 52-week range of Rs 432.10 to Rs 2,044.30. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/abbott-india-best-stock-in-its-sector\">Is Abbott India the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=venusrem-best-stock-in-its-sector\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#About_Venus_Remedies\" title=\"About Venus Remedies\">About Venus Remedies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#Is_Venus_Remedies_the_Best_Stock_in_Its_Sector\" title=\"Is Venus Remedies the Best Stock in Its Sector?\">Is Venus Remedies the Best Stock in Its Sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#How_Venus_Remedies_Compares_Against_Its_Pharmaceuticals_Sector_Peers\" title=\"How Venus Remedies Compares Against Its Pharmaceuticals Sector Peers\">How Venus Remedies Compares Against Its Pharmaceuticals Sector Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#What_Makes_Venus_Remedies_Worth_Watching_in_Pharmaceuticals\" title=\"What Makes Venus Remedies Worth Watching in Pharmaceuticals\">What Makes Venus Remedies Worth Watching in Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#Venus_Remedies_Valuation_Is_It_Justified\" title=\"Venus Remedies Valuation: Is It Justified?\">Venus Remedies Valuation: Is It Justified?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#How_to_Track_Venus_Remedies_Before_You_Invest\" title=\"How to Track Venus Remedies Before You Invest\">How to Track Venus Remedies Before You Invest<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#Is_Venus_Remedies_the_best_stock_in_its_sector\" title=\"Is Venus Remedies the best stock in its sector?\">Is Venus Remedies the best stock in its sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#What_is_the_current_share_price_of_Venus_Remedies\" title=\"What is the current share price of Venus Remedies?\">What is the current share price of Venus Remedies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#What_sector_does_Venus_Remedies_belong_to\" title=\"What sector does Venus Remedies belong to?\">What sector does Venus Remedies belong to?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#How_does_Venus_Remedies_compare_to_its_sector_peers_on_PE\" title=\"How does Venus Remedies compare to its sector peers on P\/E?\">How does Venus Remedies compare to its sector peers on P\/E?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#What_is_Venus_Remedies_return_on_equity\" title=\"What is Venus Remedies&#8217; return on equity?\">What is Venus Remedies&#8217; return on equity?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/venusrem-best-stock-in-its-sector\/#Should_I_invest_in_Venus_Remedies_based_on_its_sector_position\" title=\"Should I invest in Venus Remedies based on its sector position?\">Should I invest in Venus Remedies based on its sector position?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Venus_Remedies\"><\/span><strong>About Venus Remedies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Venus Remedies Ltd is a Panchkula based pharmaceutical company that focuses on injectable medicines. Its range includes antibiotics, oncology and critical care injectables, which it sells in India and in many overseas markets. At a market capitalisation of Rs 2,091 Cr, it is tracked as part of the Pharmaceuticals sector on Univest.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_Venus_Remedies_the_Best_Stock_in_Its_Sector\"><\/span><strong>Is Venus Remedies the Best Stock in Its Sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Venus Remedies makes its case as the best stock in its sector primarily on valuation relative to its Industry P\/E, backed by its return on equity. Venus Remedies&#8217; 18.00x P\/E is below the 36.42x Industry P\/E, Marksans Pharma at 27.32x and Ajanta Pharma at 36.31x, while its 15.49% ROE is lower than Ajanta Pharma at 23.33%, though higher than Marksans Pharma at 13.82%, and its debt to equity ratio of 0.02 is below Marksans Pharma at 0.11 and Ajanta Pharma at 0.06.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Metric<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Venus Remedies<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">CMP (NSE)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 1,572.20<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">52-Week High \/ Low<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 2,044.30 \/ Rs 432.10<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Market Cap<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 2,091 Cr<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">P\/E (TTM) vs Industry P\/E<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">18.00x vs 36.42x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">P\/B<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">3.15<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">ROE<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">15.49%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">EPS (TTM)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 86.92<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Dividend Yield<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.64%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Debt to Equity<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.02<\/td>\n<\/tr>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Venus Remedies Against Other Pharmaceuticals Sector Stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Venus_Remedies_Compares_Against_Its_Pharmaceuticals_Sector_Peers\"><\/span><strong>How Venus Remedies Compares Against Its Pharmaceuticals Sector Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets Venus Remedies against 2 other Pharmaceuticals sector names, using the same live data source for every company. A peer average row is included for P\/E, ROE and debt to equity, calculated across the 2 peer companies.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">P\/E<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Debt to Equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/venusrem\/venus-remedies-ltd-share-price-today\">Venus Remedies<\/a><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2,091<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">18.00<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">15.49%<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.02<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Marksans Pharma<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">14,236<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">27.32<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">13.82%<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.11<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">41,211<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">36.31<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">23.33%<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.06<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>Peer average (2 companies)<\/strong><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">&#8211;<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>31.82<\/strong><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>18.57%<\/strong><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>0.08<\/strong><\/td>\n<\/tr>\n<\/table>\n<p>Measured against the peer averages, Venus Remedies&#8217; P\/E is 43 percent below the 31.82x average, and its ROE is 3.08 percentage points below the 18.57% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Makes_Venus_Remedies_Worth_Watching_in_Pharmaceuticals\"><\/span><strong>What Makes Venus Remedies Worth Watching in Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Scale:<\/strong> At Rs 2,091 Cr, its market capitalisation is smaller than Marksans Pharma (Rs 14,236 Cr) and Ajanta Pharma (Rs 41,211 Cr), which is a useful reminder that the peers differ in size as well as in valuation.<\/li>\n<li><strong>Sector drivers:<\/strong> Regulated market approvals, export orders for injectables and hospital demand for antibiotics and critical care drugs shape its sales.<\/li>\n<li><strong>Key risk:<\/strong> The share has risen to about three and a half times its 52-week low, so expectations are high, and a small cap pharma name can be volatile.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Venus_Remedies_Valuation_Is_It_Justified\"><\/span><strong>Venus Remedies Valuation: Is It Justified?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At a P\/B ratio of 3.15, the market pays about Rs 3.15 for every rupee of book value, and the EPS (TTM) of Rs 86.92 is the earnings base behind the P\/E. The stock trades about 23 percent below its 52-week high and about 3.6 times its 52-week low. The dividend yield of 0.64% is a modest income component, so returns depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/ofss-best-stock-in-its-sector\">Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Venus Remedies and other Pharmaceuticals sector stocks.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Track_Venus_Remedies_Before_You_Invest\"><\/span><strong>How to Track Venus Remedies Before You Invest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Before deciding whether Venus Remedies deserves its label as the best stock in its sector for your own portfolio, compare it directly against Pharmaceuticals sector peers using the steps below.<\/p>\n<ol>\n<li>Open the Univest Screener and search for Venus Remedies to view live price, valuation ratios, and peer comparisons within the Pharmaceuticals sector.<\/li>\n<li>Compare its P\/E, P\/B, and ROE against other Pharmaceuticals sector stocks before deciding if the current valuation fits your strategy.<\/li>\n<li>Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.<\/li>\n<li>Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.<\/li>\n<\/ol>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Venus Remedies gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Pharmaceuticals depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Is_Venus_Remedies_the_best_stock_in_its_sector\"><\/span><strong>Is Venus Remedies the best stock in its sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Venus Remedies has a 15.49% ROE and trades at 18.00x P\/E against a 36.42x Industry P\/E. Against the 2 peers compared in this article, its ROE is below the 18.57% peer average and its P\/E is below the 31.82x peer average. Its debt to equity ratio of 0.02 is below the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_current_share_price_of_Venus_Remedies\"><\/span><strong>What is the current share price of Venus Remedies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Venus Remedies was trading at Rs 1,572.20 on the NSE as of 16 October 2026, and its 52-week range runs from Rs 432.10 to Rs 2,044.30. That leaves the share price 23 percent short of the 52-week high and 3.6 times the 52-week low. Its market capitalisation is Rs 2,091 Cr and its EPS (TTM) is Rs 86.92, which is the earnings figure behind the 18.00x P\/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Venus_Remedies_belong_to\"><\/span><strong>What sector does Venus Remedies belong to?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Venus Remedies is classified under the Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 36.42x Industry P\/E used in this article. The 2 named peers compared here are Marksans Pharma and Ajanta Pharma, chosen as comparable listed names so that the P\/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Venus_Remedies_compare_to_its_sector_peers_on_PE\"><\/span><strong>How does Venus Remedies compare to its sector peers on P\/E?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Venus Remedies&#8217; P\/E of 18.00x is below the 31.82x average of the 2 named peers, with Marksans Pharma at 27.32x and Ajanta Pharma at 36.31x. It also sits below the 36.42x Industry P\/E, which is the benchmark for the wider Pharmaceuticals sector. A P\/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P\/B ratio of 3.15 gives one more view of how the market values its book value.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Venus_Remedies_return_on_equity\"><\/span><strong>What is Venus Remedies&#8217; return on equity?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Venus Remedies reported a return on equity of 15.49%, which is below the 18.57% average of its named peers, with Marksans Pharma at 13.82% and Ajanta Pharma at 23.33%. ROE shows how much profit a company generates on every rupee of shareholders&#8217; equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.02 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_invest_in_Venus_Remedies_based_on_its_sector_position\"><\/span><strong>Should I invest in Venus Remedies based on its sector position?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sector position is only one input into an investment decision. Venus Remedies has a 15.49% ROE and a 18.00x P\/E, which make it worth researching further, and its dividend yield is 0.64%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Is Venus Remedies the best stock in its sector?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Venus Remedies has a 15.49% ROE and trades at 18.00x P\/E against a 36.42x Industry P\/E. Against the 2 peers compared in this article, its ROE is below the 18.57% peer average and its P\/E is below the 31.82x peer average. Its debt to equity ratio of 0.02 is below the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.\"}},{\"@type\":\"Question\",\"name\":\"What is the current share price of Venus Remedies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Venus Remedies was trading at Rs 1,572.20 on the NSE as of 16 October 2026, and its 52-week range runs from Rs 432.10 to Rs 2,044.30. That leaves the share price 23 percent short of the 52-week high and 3.6 times the 52-week low. Its market capitalisation is Rs 2,091 Cr and its EPS (TTM) is Rs 86.92, which is the earnings figure behind the 18.00x P\/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.\"}},{\"@type\":\"Question\",\"name\":\"What sector does Venus Remedies belong to?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Venus Remedies is classified under the Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 36.42x Industry P\/E used in this article. The 2 named peers compared here are Marksans Pharma and Ajanta Pharma, chosen as comparable listed names so that the P\/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.\"}},{\"@type\":\"Question\",\"name\":\"How does Venus Remedies compare to its sector peers on P\/E?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Venus Remedies' P\/E of 18.00x is below the 31.82x average of the 2 named peers, with Marksans Pharma at 27.32x and Ajanta Pharma at 36.31x. It also sits below the 36.42x Industry P\/E, which is the benchmark for the wider Pharmaceuticals sector. A P\/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P\/B ratio of 3.15 gives one more view of how the market values its book value.\"}},{\"@type\":\"Question\",\"name\":\"What is Venus Remedies' return on equity?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Venus Remedies reported a return on equity of 15.49%, which is below the 18.57% average of its named peers, with Marksans Pharma at 13.82% and Ajanta Pharma at 23.33%. ROE shows how much profit a company generates on every rupee of shareholders' equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.02 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.\"}},{\"@type\":\"Question\",\"name\":\"Should I invest in Venus Remedies based on its sector position?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sector position is only one input into an investment decision. Venus Remedies has a 15.49% ROE and a 18.00x P\/E, which make it worth researching further, and its dividend yield is 0.64%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Is Venus Remedies the best stock in its Pharmaceuticals sector? A data-driven comparison against named peers on P\/E, ROE and more.<\/p>\n","protected":false},"author":36,"featured_media":313305,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[5839,1019],"class_list":["post-313306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-sector-stocks","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["313305"],"rank_math_title":["Is Venus Remedies the Best Stock in Its Sector? A Look at the Numbers"],"rank_math_description":["Is Venus Remedies the best stock in its Pharmaceuticals sector? A data-driven comparison against named peers on P\/E, ROE and more."],"rank_math_focus_keyword":["Is Venus Remedies the Best Stock in Its Sector? A Look at the Numbers"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/is-venus-remedies-the-best-stock-in-its-sector-a-look-at-the-numbers.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/313306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=313306"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/313306\/revisions"}],"predecessor-version":[{"id":313307,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/313306\/revisions\/313307"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/313305"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=313306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=313306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=313306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}